Welcome to our dedicated page for Apogee Therapeutics news (Ticker: APGE), a resource for investors and traders seeking the latest updates and insights on Apogee Therapeutics stock.
Apogee Therapeutics, Inc. (Nasdaq: APGE) is a clinical-stage biotechnology company developing engineered biologic therapies for inflammatory and immunology (I&I) diseases, and its news flow reflects the progress and risks typical of this sector. Company announcements frequently highlight clinical trial updates for its lead IL‑13 antibody APG777 (zumilokibart) in atopic dermatitis and asthma, as well as data from earlier-stage programs such as APG279, APG333 and APG990.
Investors following APGE news can expect detailed reports on Phase 1 and Phase 2 study results, including safety, pharmacokinetics, biomarker responses and efficacy endpoints in conditions like moderate-to-severe atopic dermatitis and mild-to-moderate asthma. Recent releases have described 16-week data from the APEX Phase 2 trial in atopic dermatitis, interim Phase 1b data in asthma showing durable FeNO suppression, and first-in-human results for APG333 in healthy volunteers, all of which the company uses to frame its development strategy and dosing hypotheses.
Apogee’s news feed also covers corporate and financial milestones, such as quarterly financial results, public equity offerings under an effective shelf registration statement, and participation in healthcare and immunology conferences. These items provide context on the company’s cash runway, research and development spending, and planned timelines for future clinical readouts and potential Phase 3 trial initiations.
For readers tracking APGE, the news page offers a centralized view of regulatory filings referenced in press releases, scientific conference presentations, and management commentary on pipeline priorities. Regular updates on APG777, APG279, APG333 and related programs help investors, analysts and observers monitor how Apogee’s I&I pipeline is advancing through the clinic and how new data may influence its development plans.
Apogee Therapeutics (Nasdaq: APGE) closed an underwritten public offering of 5,750,000 common shares at $70.00 per share, including full exercise of the underwriters’ option for 750,000 additional shares, generating approximately $403 million in gross proceeds before fees.
The offering used an effective shelf registration filed August 12, 2024, and was led by Jefferies, TD Cowen, Stifel and Guggenheim.
Apogee Therapeutics (Nasdaq: APGE) priced an underwritten public offering of 5,000,000 common shares at $70.00 per share, for aggregate gross proceeds of approximately $350 million.
The offering is expected to close on March 26, 2026, subject to customary closing conditions, and underwriters have a 30-day option to purchase up to an additional 750,000 shares.
Apogee Therapeutics (Nasdaq: APGE) announced a proposed underwritten public offering of $300 million of common stock on March 23, 2026, with a 30‑day option for underwriters to purchase up to an additional $45 million.
Net proceeds are intended to fund preclinical and clinical programs, manufacturing, commercial readiness, R&D, capital expenditures, working capital and general corporate purposes. The offering is subject to market conditions and will be made by prospectus supplement under an existing registration statement.
Apogee Therapeutics (Nasdaq: APGE) reported positive 52-week Phase 2 Part A results for zumilokibart (APG777) in moderate-to-severe atopic dermatitis. The study showed durable maintenance and deepening of responses with both 3-month and 6-month maintenance dosing, and a safety profile consistent with the class.
Key metrics: EASI-75 maintenance of 75% (3-month) and 85% (6-month) and vIGA 0/1 maintenance of 86% (3-month) and 78% (6-month) among Week 16 responders. Part B 16-week induction data expected 2Q 2026; Phase 3 initiation planned for 2H 2026, with potential launch in 2029, subject to outcomes.
Apogee Therapeutics (NASDAQ: APGE) will report Part A 52-week results from the Phase 2 APEX trial of zumilokibart (APG777) on Monday, March 23, 2026. Following the announcement, the company will host a conference call and live webcast at 8:00 a.m. ET.
According to the company, the live webcast will be accessible via the Investors section on the company website and a replay will be available after the call.
Apogee Therapeutics (NASDAQ: APGE) reported full‑year 2025 results and pipeline progress, highlighting advancing clinical programs for zumilokibart (APG777) and combination candidates.
Key points: APEX Phase 2 Part A 52‑week maintenance readout expected March 2026; Part B 16‑week readout in Q2 2026; Phase 3 initiation targeted 2H 2026. Cash was $902.9M at year‑end, providing runway into 2H 2028. Positive Phase 1b asthma data and a head‑to‑head APG279 vs DUPIXENT study readout expected 2H 2026.
Apogee Therapeutics (Nasdaq: APGE) announced management will participate in three investor events in early March 2026: a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, and attendance at the UBS Biotech Summit Miami (March 9) and Jefferies Biotech on the Beach Summit (March 10). A live and archived webcast of the March 3 fireside chat will be available on the company’s Investors News & Events page.
Apogee Therapeutics (Nasdaq: APGE) said company management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 2:00 p.m. ET.
A live and archived webcast will be available via the News & Events page in the Investors section of Apogee Therapeutics' website.
Apogee Therapeutics (NASDAQ: APGE) reported positive interim Phase 1b results for zumilokibart (APG777) in 19 adults with mild-to-moderate asthma, showing a maximum mean FeNO reduction of 45 ppb (60% from baseline) after one 720 mg dose and durable FeNO suppression through 16 weeks (and through 32 weeks for patients with follow-up).
Zumilokibart was well tolerated with no Grade 3+ TEAEs, no conjunctivitis, injection-site reactions, or ADAs. Company highlights expected 2026 milestones: APEX Part A 52-week data in Q1 2026, Part B 16-week induction data in Q2 2026 (Part B enrolled 347 patients), potential Phase 3 start in 2H 2026, and a potential commercial launch in 2029. Cash of $913 million provides runway into 2H 2028.
Apogee Therapeutics (Nasdaq: APGE) will report interim results from its Phase 1b trial of APG777 in patients with mild-to-moderate asthma on Tuesday, January 6, 2026.
The company will host a conference call and live webcast on January 6, 2026 at 8:00 a.m. ET to discuss the interim data. The live webcast can be accessed via the company’s investor website at https://investors.apogeetherapeutics.com/news-events/events and a replay will be available after the call.